POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its financial results for the period ended June 30, 2023 and provided a corporate update.
